Novartis/Schering AG Re-Evaluating PTK/ZK Development Due To Low Probability Of Survival Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms plan to reconsider NDA submission strategy after interim analysis of CONFIRM-2 trial suggests PTK/ZK 787 is unlikely to yield survival benefit in second-line metastatic colorectal cancer.